Dexcom Investor Relations Material
Latest events
Q1 2025
Dexcom
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Dexcom Inc
Access all reports
Dexcom, Inc., focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company's products include Dexcom G4 PLATINUM System, Dexcom G5 Mobile CGM System, and its interoperable systems, as well as other clinical diagnostic products. It offers its products to hospitals; physicians' offices specializing in diabetes treatment; ambulatory surgical centers; clinical practice settings; corporate wellness programs; and individual patients. The company markets its products directly to physicians and their specialties, including endocrinologists; general practitioners; obstetricians/gynecologists; pediatricians; family physicians; doctors practicing in health care clinics or managed facilities; diabetologists; and internists. The company was incorporated in 1999.
Key slides for Dexcom Inc
Q1 2025
Dexcom Inc
Raymond James & Associates’ 46th Annual Institutional Investors Conference 2025
Dexcom Inc
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
DXCM
Country
🇺🇸 United States